Hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) is a dominantly inherited syndrome characterized by the development of colorectal cancer, endometrial cancer and other cancers and the presence of microsatellite instability (MSI) in tumors. The Bethesda guidelines have been proposed for the identification of families suspected of HNPCC that require further molecular analysis. We...

β-catenin, an epithelial-mesenchymal transition (EMT)-associated marker, is key in the progression of colorectal cancer (CRC). However, the prognostic significance of β-catenin expression in patients with CRC remains controversial. In the present study, the expression of β-catenin at the tumor invasive front and the tumor center was investigated, and the correlations amongst β-catenin different...

MicroRNA-126 (miR-126) has been reported to be a tumor suppressor that targets CXCR4 in colorectal cancer (CRC) cells. This study investigated whether miR-126 has any prognostic impact in patients with CRC. MiR-126 and CXCR4 mRNA expression in 92 pairs of CRC and adjacent nontumorous tissues was examined using quantitative real-time PCR, and CXCR4 protein expression was assessed by immunohistoc...

Background: Evaluation of mismatch repair (MMR) status in colorectal cancer (CRC) could be used as the guidance for postsurgical treatment. Defective MMR status is associated with distinct clinicopathological features. This study aims to evaluate associations between MMR status and clinicopathological features in a retrospective cohort of consecutive Chinese CRC patients. Methods: Clinicopathol...

ALK rearrangements have been observed in 0.05%-2.5% of patients with colorectal cancers (CRCs) and are predicted to be oncogenic drivers largely mutually exclusive of KRAS, NRAS, or BRAF alterations. Here we present the case of a patient with metastatic CRC who was treatment naïve at the time of molecular testing. Initial ALK immunohistochemistry (IHC) staining was negative, but parallel genomi...

BRAF mutations can be found in various solid tumors. But accurate and reliable screening for BRAF mutation that is compatible for clinical application is not yet available. In this study, we used an automated immunohistochemistry (IHC) staining coupled with mouse monoclonal anti-BRAF V600E (VE1) primary antibody to screen the BRAF V600E mutation in 779 tumor cases, including 611 colorectal carc...